$Lantern Pharma (LTRN.US)$
START BUYING DRUG APPROVAL COMING SOON

$Lantern Pharma (LTRN.US)$ Elon will bring this 🚀🚀🚀 soon….

$Lantern Pharma (LTRN.US)$ 🚀🚀🚀

$Lantern Pharma (LTRN.US)$
Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer
Monday, 27th January at 7:55 am
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced advancements in the application of its RADR® AI platform to a...

$Lantern Pharma (LTRN.US)$
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
Monday, 9th December at 8:15 am
Multiple clinical trial sites across Taiwan are actively screening patients, following successful site initiation visits.
Expansion into Taiwan is particularly significant as over 50% of lung cancer cases in Taiwan occur in never-smokers.
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence...

$Lantern Pharma (LTRN.US)$ Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
5 MINUTES AGO, 8:00 AM EST
VIA BUSINESSWIRE

$Lantern Pharma (LTRN.US)$
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
Tuesday, 3rd December at 8:00 am
• This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024.
• Fast Track Designation for LP-184 recognizes TNBC as a serious condition impacting approximately 29,000 patients annually in th...

$Lantern Pharma (LTRN.US)$
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
Lantern Pharma and its subsidiary Starlight Therapeutics presented new preclinical data and Phase 1b trial design for LP-184 (STAR-001) in glioblastoma at SNO 2024.
The data shows LP-184 combined with spironolactone increases GBM cell sensitivity up to 6-fold thro...